Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone in Metastatic Breast Cancer
This open-label phase 2 randomized clinical trial evaluates the safety and efficacy of vistusertib in combination with fulvestrant compared with fulvestrant alone or fulvestrant plus everolimus for women with hormone receptor–positive metastatic breast cancer.